Welcome to our dedicated page for CINCOR PHARMA news (Ticker: CINC), a resource for investors and traders seeking the latest updates and insights on CINCOR PHARMA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CINCOR PHARMA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CINCOR PHARMA's position in the market.
CinCor Pharma, a clinical-stage biopharmaceutical company, announced the pricing of its initial public offering (IPO) of 12,100,000 shares at $16.00 per share, aiming for gross proceeds of $193.6 million. The shares will trade on the Nasdaq under the symbol 'CINC', starting January 7, 2022. The underwriters have a 30-day option to purchase an additional 1,815,000 shares. Morgan Stanley, Jefferies, and Evercore ISI are the joint book-running managers for the offering. This IPO is crucial for funding the development of CinCor's lead candidate, CIN-107, targeting hypertension and cardio-renal diseases.
CinCor Pharma has initiated an initial public offering (IPO) of 11,000,000 shares of its common stock, with an expected pricing range of $15 to $17 per share. The offering aims to support the development of CIN-107, a candidate for treating hypertension and cardio-renal diseases. Additionally, the underwriters may purchase up to 1,650,000 additional shares. Shares will trade on NASDAQ under the symbol CINC. The offering's completion is subject to market conditions.